Opus Genetics' OPGx — BEST1 improves retinal sensitivity in 75% of evaluable patients in early — stage trial
Opus Genetics presented positive clinical results for its OPGx-LCA5 and OPGx-BEST1 gene therapies at Retina in Rio 2026. OPGx-LCA5 showed sustained vision improvements in adults through 24 months, with encouraging pediatric results through six months. The fully enrolled OPGx-LCA5 Phase 3 trial is expected to begin dosi